March 21, 2001
Irvine biopharmaceutical company NeoTherapeutics Inc. incurred a net loss of $11.5 million, or 88 cents a share, for the fourth quarter, down from a net loss of $12.2 million, or $1.47 a share, for the 1999 fourth quarter, which included a charge of $2.5 million for a legal settlement. For the year, the company posted a net loss of $46.4 million, or $4.37 a share, compared with a 1999 net loss of $26 million, or $3.68 a share. The development-stage company reported no revenue.
March 20, 2001 |
Investors swept up shares of NeoTherapeutics Inc. on Monday after the Irvine biopharmaceutical company announced a license agreement with Pfizer Inc. worth up to $12 million. NeoTherapeutics, which until now has not generated revenue, will receive an initial payment from Pfizer.
February 8, 2001 |
NeoTherapeutics Inc.'s climbing stock moved up an additional 30% Wednesday, snapped up by investors after the company said it is planning a pivotal study of its drug compound for treating Alzheimer's disease. The Irvine biopharmaceutical company also said this week that a subsidiary received $7 million in new financing. The stock, which rose 15% on Tuesday and 14% on Monday, closed Wednesday at $4.16, up 97 cents a share in Nasdaq trading. A total of 1.
January 3, 2001 |
NeoTherapeutics Inc. filed a shelf registration statement with the Securities and Exchange Commission to issue up to $50 million of debt securities, stock, depositary shares or warrants. The Irvine biopharmaceutical company said Tuesday the filing allows it "speed and flexibility" when market conditions are attractive. A shelf filing lets the company register securities in advance and sell them from time to time as needed.
December 19, 2000 |
NeoTherapeutics Inc. said clinical data from a study of its nerve-regeneration drug Neotrofin showed the treatment facilitates brain activity in Alzheimer's disease patients. The Irvine biopharmaceutical company said the study, which treated 19 patients with Neotrofin, resulted in significant improvement in memory, attention and judgment.
November 4, 2000
The Irvine biopharmaceutical incurred a third-quarter net loss of $13.2 million, or $1.27 a share, which included a noncash charge of $1 million from the sale of convertible preferred stock of its NeoGene unit. The net loss for the same period last year was $5.3 million, or 70 cents a share. Revenue was not reported.